121 related articles for article (PubMed ID: 15134183)
1. Comparison of two reduced-dose regimens of indinavir (600 mg vs 400 mg twice daily) and ritonavir (100 mg twice daily) in healthy volunteers (COREDIR).
Wasmuth JC; la Porte CJ; Schneider K; Burger DM; Rockstroh JK
Antivir Ther; 2004 Apr; 9(2):213-20. PubMed ID: 15134183
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetic profile and tolerability of indinavir-ritonavir combinations in healthy volunteers.
Saah AJ; Winchell GA; Nessly ML; Seniuk MA; Rhodes RR; Deutsch PJ
Antimicrob Agents Chemother; 2001 Oct; 45(10):2710-5. PubMed ID: 11557459
[TBL] [Abstract][Full Text] [Related]
3. Comparison of indinavir + ritonavir 600 + 100 mg vs. 400 + 100 mg BID combinations in HIV1-infected patients guided by therapeutic drug monitoring.
Wasmuth JC; Rodermann E; Voigt E; Vogel M; Lauenroth-Mai E; Jessen A; Burger D; Rockstroh JK
Eur J Med Res; 2007 Jul; 12(7):289-94. PubMed ID: 17933700
[TBL] [Abstract][Full Text] [Related]
4. Indinavir/ritonavir-based therapy in HIV-1-infected antiretroviral therapy-naive patients: comparison of 800/100 mg and 400/100 mg twice daily.
Konopnicki D; De Wit S; Poll B; Crommentuyn K; Huitema A; Clumeck N
HIV Med; 2005 Jan; 6(1):1-6. PubMed ID: 15670245
[TBL] [Abstract][Full Text] [Related]
5. Administration of indinavir and low-dose ritonavir (800/100 mg twice daily) with food reduces nephrotoxic peak plasma levels of indinavir.
Aarnoutse RE; Wasmuth JC; Fätkenheuer G; Schneider K; Schmitz K; de Boo TM; Reiss P; Hekster YA; Burger DM; Rockstroh JK
Antivir Ther; 2003 Aug; 8(4):309-14. PubMed ID: 14518700
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics of reduced-dose indinavir/ritonavir 400/100 mg twice daily in HIV-1-infected Thai patients.
Boyd M; Mootsikapun P; Burger D; Chuenyam T; Ubolyam S; Mahanontharit A; Sangkote J; Bunyaprawit P; Horsakulchai M; Lange J; Cooper D; Phanuphak P; Ruxrungtham K
Antivir Ther; 2005; 10(2):301-7. PubMed ID: 15865224
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics of indinavir and ritonavir administered at 667 and 100 milligrams, respectively, every 12 hours compared with indinavir administered at 800 milligrams every 8 hours in human immunodeficiency virus-infected patients.
Rhame FS; Rawlins SL; Petruschke RA; Erb TA; Winchell GA; Wilson HM; Edelman JM; Abramson MA
Antimicrob Agents Chemother; 2004 Nov; 48(11):4200-8. PubMed ID: 15504842
[TBL] [Abstract][Full Text] [Related]
8. Boosted versus unboosted indinavir with zidovudine and lamivudine in nucleoside pre-treated patients: a randomized, open-label trial with 112 weeks of follow-up (HIV-NAT 005).
Boyd MA; Srasuebkul P; Khongphattanayothin M; Ruxrungtham K; Hassink EA; Duncombe CJ; Ubolyam S; Burger DM; Reiss P; Stek M; Lange J; Cooper DA; Phanuphak P
Antivir Ther; 2006; 11(2):223-32. PubMed ID: 16640103
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetic study of the variability of indinavir drug levels when boosted with ritonavir in HIV-infected children.
Curras V; Hocht C; Mangano A; Niselman V; Mariño Hernández E; Cáceres Guido P; Mecikovsky D; Bellusci C; Bologna R; Sen L; Rubio MC; Bramuglia GF
Pharmacology; 2009; 83(1):59-66. PubMed ID: 19052483
[TBL] [Abstract][Full Text] [Related]
10. Dose-finding study of a once-daily indinavir/ritonavir regimen.
Hugen PW; Burger DM; ter Hofstede HJ; Koopmans PP; Stek M; Hekster YA; Reiss P; Lange JM
J Acquir Immune Defic Syndr; 2000 Nov; 25(3):236-45. PubMed ID: 11115954
[TBL] [Abstract][Full Text] [Related]
11. Health-related quality of life in HIV patients switching to twice-daily indinavir/ritonavir regimen or continuing with three-times-daily indinavir-based therapy.
Badía X; Podzamczer D; Moral I; Roset M; Arnaiz JA; Loncà M; Casiró A; Rosón B; Gatell JM;
Antivir Ther; 2004 Dec; 9(6):979-85. PubMed ID: 15651756
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics and 48 week efficacy of adjusted dose indinavir/ritonavir in rifampicin-treated HIV/tuberculosis-coinfected patients: a pilot study.
Avihingsanon A; van der Lugt J; Singphore U; Gorowara M; Boyd M; Ananworanich J; Phanuphak P; Burger D; Ruxrungtham K
AIDS Res Hum Retroviruses; 2012 Oct; 28(10):1170-6. PubMed ID: 22250979
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics and tolerability of a combination of indinavir, lopinavir and ritonavir in multiply pretreated HIV-1 infected adults.
von Hentig N; Müller A; Rottmann C; Lutz T; Klauke S; Kurowski M; Staszewski S; Harder S
Eur J Med Res; 2006 Jun; 11(6):236-44. PubMed ID: 16820336
[TBL] [Abstract][Full Text] [Related]
14. Low-doses of indinavir boosted with ritonavir in HIV-infected Thai patients: pharmacokinetics, efficacy and tolerability.
Cressey TR; Leenasirimakul P; Jourdain G; Tod M; Sukrakanchana PO; Kunkeaw S; Puttimit C; Lallemant M
J Antimicrob Chemother; 2005 Jun; 55(6):1041-4. PubMed ID: 15883177
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics of atazanavir/ritonavir once daily and lopinavir/ritonavir twice and once daily over 72 h following drug cessation.
Boffito M; Else L; Back D; Taylor J; Khoo S; Sousa M; Pozniak A; Gazzard B; Moyle G
Antivir Ther; 2008; 13(7):901-7. PubMed ID: 19043924
[TBL] [Abstract][Full Text] [Related]
16. Association of total bilirubin with indinavir and lopinavir plasma concentrations in HIV-infected patients receiving three different double-boosted dosing regimens.
Dicenzo R; Luque A; Larppanichpoonphol P; Reichman R
J Antimicrob Chemother; 2006 Aug; 58(2):393-400. PubMed ID: 16760191
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics and pharmacodynamics of indinavir with or without low-dose ritonavir in HIV-infected Thai patients.
Burger D; Boyd M; Duncombe C; Felderhof M; Mahanontharit A; Ruxrungtham K; Ubolyam S; Stek M; Cooper D; Lange J; Phanupak P; Reiss P
J Antimicrob Chemother; 2003 May; 51(5):1231-8. PubMed ID: 12668574
[TBL] [Abstract][Full Text] [Related]
18. Maintenance of indinavir by dose adjustment in HIV-1-infected patients with indinavir-related toxicity.
Wasmuth JC; Lambertz I; Voigt E; Vogel M; Hoffmann C; Burger D; Rockstroh JK
Eur J Clin Pharmacol; 2007 Oct; 63(10):901-8. PubMed ID: 17690876
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics of darunavir/ritonavir and TMC125 alone and coadministered in HIV-negative volunteers.
Schöller-Gyüre M; Kakuda TN; Sekar V; Woodfall B; De Smedt G; Lefebvre E; Peeters M; Hoetelmans RM
Antivir Ther; 2007; 12(5):789-96. PubMed ID: 17713162
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetic and safety evaluation of high-dose combinations of fosamprenavir and ritonavir.
Shelton MJ; Wire MB; Lou Y; Adamkiewicz B; Min SS
Antimicrob Agents Chemother; 2006 Mar; 50(3):928-34. PubMed ID: 16495253
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
